Angiotensin-II type 1 receptor-mediated hypertension in D4 dopamine receptor-deficient mice

Martin J Bek1, Xiaoyan Wang, Laureano D Asico

  • 1Department of Pediatrics, Georgetown University Medical Center, Washington, DC 20057, USA.

Insights

Mice lacking dopamine D4 receptors show higher blood pressure, potentially due to increased angiotensin II type 1 receptor expression in the kidney and brain. This suggests a novel role for D4 receptors in blood pressure regulation.

Area of Science:

  • Cardiovascular Physiology
  • Neuropharmacology
  • Renal Physiology

Background:

  • Dopamine receptors play a role in systemic blood pressure regulation.
  • Dopamine D4 receptors are found in the kidney and brain, but their cardiovascular function is unclear.

Purpose of the Study:

  • To investigate the role of dopamine D4 receptors in cardiovascular regulation.
  • To determine the impact of D4 receptor deficiency on blood pressure and related signaling pathways.

Main Methods:

  • Compared blood pressure in D4 receptor-deficient (D4(-/-)) and wild-type (D4(+/+)) mice under anesthetized and conscious conditions.
  • Measured renin concentrations and angiotensin II type 1 receptor (AT1R) protein expression in kidney and brain.
  • Administered AT1R antagonist losartan to assess its hypotensive effects in both genotypes.

Main Results:

  • D4(-/-) mice exhibited elevated systolic and diastolic blood pressures compared to D4(+/+) littermates.
  • Increased AT1R protein expression was observed in the kidney and brain of D4(-/-) mice.
  • The hypotensive effect of losartan was prolonged in D4(-/-) mice, indicating altered AT1R signaling.

Conclusions:

  • Absence of the dopamine D4 receptor leads to increased blood pressure.
  • This hypertension may be mediated by enhanced angiotensin II type 1 receptor expression and signaling.
  • Dopamine D4 receptors are implicated in the regulation of blood pressure, possibly through the renin-angiotensin system.

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...